Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19
- https://doi.org/10.2991/icres.k.210406.001How to use a DOI?
- COVID-19, Tocilizumab, preliminary efficacy, safety
Background: Interleukin-6 (IL-6) was considered to be with the severity and mortality in COVID-19 patients, which implies a potential therapeutic target for treatment. We aimed to evaluate the safety and initial efficacy of Tocilizumab treatment for COVID-19 patients.
Methods: In the retrospective study, 61 patients with COVID-19 with the mean age of 69 were enrolled from February 27 to March 14, 2020 in Wuhan Huoshenshan Hospital. Twenty-nine of them received one dose (400 mg) of add-on Tocilizumab treatment as the treated group and remaining 32 cases served as control group. The clinical manifestations and laboratory examinations were compared between the two groups.
Results: The average duration of symptoms appeal to hospital admission was 28.2 days. Compared with the cases in control group, the treated cases exhibited a significant increase of serum IL-6 on the 7th day since Tocilizumab injection, however, there were no differences in whole blood white cell count, circulating lymphocyte count, serum C-reactive protein (CRP), and respiratory parameters or other clinical manifestations between the treated and control groups. There were no adverse events associated with Tocilizumab treatment in the treated COVID-19 patients.
Conclusion: In the patients with COVID-19, one dose of Tocilizumab treatment was safe but no clinical benefit was observed on the 7th day in this study.
- Chinese Abstract
背景：白细胞介素 6 (IL-6)表达水平与COVID-19 患者疾病严重程度和病死率密切相关，是临床治疗潜在治疗靶点。 我们旨在评估托珠单抗治疗 COVID-19 患者的安全性和有效性。
结论：在 COVID-19 患者中，托珠单抗治疗是安全的，但在本研究的未观察到临床获益。
- © 2021 First Affiliated Hospital of Zhengzhou University. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Yu Chen AU - Xijing Zhang PY - 2021 DA - 2021/04/10 TI - Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19 JO - Intensive Care Research SP - 24 EP - 30 VL - 1 IS - 1-2 SN - 2666-9862 UR - https://doi.org/10.2991/icres.k.210406.001 DO - https://doi.org/10.2991/icres.k.210406.001 ID - Chen2021 ER -